Liquidia Corporation (LQDA)
NASDAQ: LQDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
LQDA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.39B
- P/E (TTM)
- 19.19
- Forward P/E
- 11.10
- EPS (TTM)
- $1.39
- Dividend yield
- None
- 52-week range
- 21.94 – 93.61
- Day range
- 24.59 – 27.33
- Volume / Avg
- 6.96M / 2.32M
- Beta
- —
- Shares outstanding
- 89.51M
- Next earnings
- Nov 2, 2026
52-week range
LQDA stock today
Shares of Liquidia (LQDA) finished higher on Oct 7 at $26.68, a gain of 2.97% or $0.77 per share, versus the S&P 500's 0.22% decline. Volume was 3.0x the average at 6.96M shares, a sign of unusually heavy trading. At this level, LQDA sits near the bottom of its 52-week range of $21.94 to $93.61: 71.5% below the high, set on Aug 11, 2026 and 21.6% above the low.
LQDA is down 22.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 11.0%. Liquidia trades at 19.2x its trailing twelve-month earnings per share of $1.39. Its forward P/E of 11.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Liquidia's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Liquidia
Company profileLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Roger A. Jeffs Ph.D.
- Headquarters
- Morrisville, NC
- Employees
- 216
- IPO year
- 2018
- Website
- liquidia.com
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$49.67+86.17%
- Strong buy 2
- Buy 2
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $0.77
Liquidia peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs LQDA |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs LQDA |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs LQDA |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs LQDA |
| NRIXNurix Therapeutics Inc. | 22.73 | +0.58% | $2.36B | vs LQDA |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs LQDA |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs LQDA |
| PHVSPharvaris N.V. | 31.68 | +1.80% | $2.22B | vs LQDA |
Indexes, lists and sector
Liquidia stock FAQ
What is Liquidia's stock price today?
LQDA last traded at $26.68 as of Oct 7, 4:00 PM EDT, up 2.97% on the day. Prices are delayed at least 15 minutes.
When is Liquidia's next earnings date?
Liquidia is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $0.77.
What is LQDA's P/E ratio?
LQDA trades at a trailing P/E ratio of 19.19 and a forward P/E of 11.10.
Who is Liquidia's CEO?
Dr. Roger A. Jeffs Ph.D. is the chief executive officer of Liquidia Corporation, which has about 216 employees.
What is the LQDA 52-week high?
The 52-week high for LQDA is $93.61 and the 52-week low is $21.94. The stock is currently 71.5% below its high.